US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax

509
24
Favorite

US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax

Renaissance Capital2022-04-30

Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

509

Report

Comment（24）

sh99
·2022-04-30
dm kim
Reply
1
Report
DrSam
·2022-04-30
FAANG
Reply
2
Report
BhaskarB
·2022-04-30
Like ok
Reply
1
Report
yeelyn18
·2022-04-30
K
Reply
2
Report
parie
·2022-04-30
Buy!
Reply
Like
Report
Jahme
·2022-04-30
Sigh
Reply
1
Report
shoude
·2022-04-30
Like and comment
Reply
1
Report
HENRYCSC
·2022-04-30
Like pls
Reply
1
Report
SeanSak
·2022-04-30
Like n comment
Reply
1
Report
sfleong1
·2022-04-30
Like n comment
Reply
2
Report
willwees
·2022-04-30
Like pls
Reply
4
Report
JohnL
·2022-04-30
Noted
Reply
4
Report
YJ Lee
·2022-04-30
Ok
Reply
5
Report
jethro
·2022-04-30
good
Reply
3
Report
Zwei2
·2022-04-30
K
Reply
3
Report
FT585
·2022-04-30
Like
Reply
4
Report
WalkerWoon
·2022-04-30
Ok
Reply
3
Report
WaiSiong81
·2022-04-30
👍
Reply
6
Report
vaicrazy
·2022-04-30
Ok
Reply
4
Report
ToTheM00N
·2022-04-30
Like pls
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1117481794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-30 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117481794","market":"us","top_or_hot":-1,"title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","media":"Renaissance Capital","content":"<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Source Link</a>\n\n</div>\n","source":"lsy1603787993745","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OST","symbol_name":"奥斯汀科技集团","start_time":0,"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","article_id":"1117481794","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","pubTimestamp":1651282497,"columns":[],"sourceInfo":{"source_id":"lsy1603787993745","name":"Renaissance Capital"},"weMediaInfo":null,"summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","collect":0,"end_time":0,"defaultTopTitle":"renaissancecapital.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc.","BLTE":"Belite Bio, Inc."},"translate_title":"美国IPO周报：4个IPO价格，诺如病毒生物科技HilleVax领跑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLTE":0.9,"OST":0.9,"TNON":0.9},"content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9069597471,"gmtCreate":1651307141971,"gmtModify":1676534888213,"author":{"id":"3582013951378523","authorId":"3582013951378523","name":"sh99","avatar":"https://static.tigerbbs.com/95985dfcd15851145b63b9903fdb5bfc","vip":1,"hat":"https://static.tigerbbs.com/6444b4970948c1077534c593eccd6d16","crmLevel":4,"crmLevelSwitch":0,"idStr":"3582013951378523","authorIdStr":"3582013951378523"},"htmlText":"dm kim","listText":"dm kim","text":"dm kim","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069597471","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069270737,"gmtCreate":1651300598600,"gmtModify":1676534887429,"author":{"id":"3582967351944758","authorId":"3582967351944758","name":"DrSam","avatar":"https://static.tigerbbs.com/2161cecb6376985512402ff4b6052ccc","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3582967351944758","authorIdStr":"3582967351944758"},"htmlText":"FAANG&nbsp;","listText":"FAANG&nbsp;","text":"FAANG","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069270737","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069259349,"gmtCreate":1651296856899,"gmtModify":1676534886973,"author":{"id":"3576055655100541","authorId":"3576055655100541","name":"BhaskarB","avatar":"https://static.tigerbbs.com/ae63d5d863287dbf3e7d25ef9ab845e0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576055655100541","authorIdStr":"3576055655100541"},"htmlText":"Like ok","listText":"Like ok","text":"Like ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069259349","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069221743,"gmtCreate":1651295409428,"gmtModify":1676534886822,"author":{"id":"3574914526090483","authorId":"3574914526090483","name":"yeelyn18","avatar":"https://static.tigerbbs.com/ae47c3e96729c68a0234dd22850dfe69","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574914526090483","authorIdStr":"3574914526090483"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069221743","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069223609,"gmtCreate":1651295245030,"gmtModify":1676534886785,"author":{"id":"3586604412538634","authorId":"3586604412538634","name":"parie","avatar":"https://community-static.tradeup.com/news/c31cfaba24add90d5bcc2dde0c06c5d5","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586604412538634","authorIdStr":"3586604412538634"},"htmlText":"Buy!","listText":"Buy!","text":"Buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069223609","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069262928,"gmtCreate":1651294288039,"gmtModify":1676534886614,"author":{"id":"3577502940596690","authorId":"3577502940596690","name":"Jahme","avatar":"https://static.tigerbbs.com/d07b4bec5131f225dae7aadbfebc0c02","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577502940596690","authorIdStr":"3577502940596690"},"htmlText":"Sigh&nbsp;","listText":"Sigh&nbsp;","text":"Sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069262928","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069262052,"gmtCreate":1651294240499,"gmtModify":1676534886639,"author":{"id":"3587029173183468","authorId":"3587029173183468","name":"shoude","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3587029173183468","authorIdStr":"3587029173183468"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069262052","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069289093,"gmtCreate":1651291934360,"gmtModify":1676534886245,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069289093","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069211807,"gmtCreate":1651290630055,"gmtModify":1676534886072,"author":{"id":"3581585664475701","authorId":"3581585664475701","name":"SeanSak","avatar":"https://static.tigerbbs.com/4a62d3d455150e01d4dc6c67bd4f9c0d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581585664475701","authorIdStr":"3581585664475701"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069211807","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069232199,"gmtCreate":1651289740560,"gmtModify":1676534885808,"author":{"id":"3583570345500843","authorId":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583570345500843","authorIdStr":"3583570345500843"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069232199","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069293385,"gmtCreate":1651287832976,"gmtModify":1676534885494,"author":{"id":"4087526584403100","authorId":"4087526584403100","name":"willwees","avatar":"https://community-static.tradeup.com/news/bc2de1dfc9923a23848d1c226adff6c7","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":0,"idStr":"4087526584403100","authorIdStr":"4087526584403100"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069293385","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069290314,"gmtCreate":1651287589949,"gmtModify":1676534885452,"author":{"id":"3570369418287680","authorId":"3570369418287680","name":"JohnL","avatar":"https://community-static.tradeup.com/news/20db2fa4f65cb04a8d837d400a1b5d7b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3570369418287680","authorIdStr":"3570369418287680"},"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069290314","repostId":1117481794,"repostType":2,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069201363,"gmtCreate":1651286791027,"gmtModify":1676534885203,"author":{"id":"4108816210230400","authorId":"4108816210230400","name":"YJ Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4108816210230400","authorIdStr":"4108816210230400"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069201363","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069201982,"gmtCreate":1651286783448,"gmtModify":1676534885202,"author":{"id":"4103089604754610","authorId":"4103089604754610","name":"jethro","avatar":"https://static.tigerbbs.com/445b4765728802a2e3b3795587bae0a3","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":6,"crmLevelSwitch":1,"idStr":"4103089604754610","authorIdStr":"4103089604754610"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069201982","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069677316,"gmtCreate":1651286358554,"gmtModify":1676534885095,"author":{"id":"3580356429010047","authorId":"3580356429010047","name":"Zwei2","avatar":"https://static.tigerbbs.com/9d0132a4cde9155d859c3873325d194e","vip":1,"hat":"https://static.tigerbbs.com/646756f1284a5a6480ed02cc4fa7d1d2","crmLevel":7,"crmLevelSwitch":0,"idStr":"3580356429010047","authorIdStr":"3580356429010047"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069677316","repostId":1117481794,"repostType":2,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069674775,"gmtCreate":1651286338498,"gmtModify":1676534885088,"author":{"id":"3562726241279787","authorId":"3562726241279787","name":"FT585","avatar":"https://static.tigerbbs.com/734b50619b12425294cb4715814bdedb","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3562726241279787","authorIdStr":"3562726241279787"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069674775","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069675759,"gmtCreate":1651286210387,"gmtModify":1676534885063,"author":{"id":"3567211702241491","authorId":"3567211702241491","name":"WalkerWoon","avatar":"https://static.tigerbbs.com/a772c81a4c88b39f7cdec13c1c0af077","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3567211702241491","authorIdStr":"3567211702241491"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069675759","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069644271,"gmtCreate":1651285470834,"gmtModify":1676534884758,"author":{"id":"4092698747642690","authorId":"4092698747642690","name":"WaiSiong81","avatar":"https://static.tigerbbs.com/81c10c8d3ad2387a719eaa62a541371f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4092698747642690","authorIdStr":"4092698747642690"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069644271","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069645511,"gmtCreate":1651285393916,"gmtModify":1676534884734,"author":{"id":"3573989963279471","authorId":"3573989963279471","name":"vaicrazy","avatar":"https://static.tigerbbs.com/5e1fe01bd5dda3f3a00e7197697a8873","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3573989963279471","authorIdStr":"3573989963279471"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069645511","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9069649906,"gmtCreate":1651284828847,"gmtModify":1676534884507,"author":{"id":"3581730511233431","authorId":"3581730511233431","name":"ToTheM00N","avatar":"https://static.tigerbbs.com/7b77b689650adddd8a8560dc89fcb930","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581730511233431","authorIdStr":"3581730511233431"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9069649906","repostId":1117481794,"repostType":4,"repost":{"id":"1117481794","kind":"news","pubTimestamp":1651282497,"share":"https://ttm.financial/m/news/1117481794?lang=&edition=fundamental","pubTime":"2022-04-30 09:34","market":"us","language":"en","title":"US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax","url":"https://stock-news.laohu8.com/highlight/detail?id=1117481794","media":"Renaissance Capital","summary":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). T","content":"<html><head></head><body><p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.</p><p>The week&#39;s biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.</p><p>HilleVax&#39;s upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.</p><p>The week&#39;s three micro-cap IPOs included Chinese display supplier <a href=\"https://laohu8.com/S/OST\">Ostin Technology Group</a>, medical implant developer <a href=\"https://laohu8.com/S/TNON\">Tenon Medical</a>, and retinal degeneration biotech <a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a>. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.</p><p>The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.</p><p><img src=\"https://static.tigerbbs.com/a0acc550464478d88572e6ed3bb9e9f3\" tg-width=\"701\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/><img src=\"https://static.tigerbbs.com/b886b5a7ae49823d890df7203c145483\" tg-width=\"705\" tg-height=\"257\" referrerpolicy=\"no-referrer\"/>IPO Market Snapshot</p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&amp;P 500 was down 9.7%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 4 IPOs Price, Led By Norovirus Biotech HilleVax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-30 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLTE":"Belite Bio, Inc.","OST":"奥斯汀科技集团","TNON":"Tenon Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/92347/US-IPO-Weekly-Recap-4-IPOs-price-led-by-norovirus-biotech-HilleVax","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117481794","content_text":"Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum traders. Three SPACs also raised a combined $245 million, targeting Asian fintech, sustainable energy, and technology.The week's biggest news came from Bausch + Lomb (BLCO), which set terms to raise about $800 million in the coming week at a valuation north of $8 billion.HilleVax's upsized offering raised $200 million, making it the largest biotech IPO so far this year, out of nine total. The stock finished up 12%, bucking the recent sell-off in the biotech space. Backed by Frazier Healthcare Partners, HilleVax is in Phase 2 trials for a novel norovirus vaccine, which it licenses from former parent Takeda Pharma. While the company has just one clinical-stage candidate, it is going after a massive market, with the potential to be approved in routine infant vaccinations.The week's three micro-cap IPOs included Chinese display supplier Ostin Technology Group, medical implant developer Tenon Medical, and retinal degeneration biotech Belite Bio. Ostin Technology soared an eye-popping 892% on its debut, the biggest IPO pop in about a year, before wiping out all of its gains later in the week.The IPO Index fell to a 52-week low on Friday, a clear signal of the extremely challenging environment for US IPOs, especially growth names.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 4/28/2022, the Renaissance IPO Index was down 36.0% year-to-date, while the S&P 500 was down 9.7%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and CrowdStrike Holdings (CRWD). The Renaissance International IPO Index was down 30.9% year-to-date, while the ACWX was down 12.3%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":509,"commentSize":24,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}